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Abstract
Background: The complement system has been implicated in pathogenesis of systemic sclerosis (SSc). The goal of
the present study was to evaluate improved complement biomarkers in SSc.
Methods: The presence of C4d, reflecting activation of the classical/lectin pathways, C3bBbP corresponding to
activation of the alternative pathway, and soluble terminal complement complexes (all complement pathways),
was measured in plasma samples by enzyme-linked immunosorbent assay and correlated to clinical parameters.
The study included 81 patients with limited cutaneous SSc and 41 with diffuse cutaneous SSc, as well as 47
matched healthy controls and 81 patients with rheumatoid arthritis, 22 with psoriatic arthritis and 20 with
ankylosing spondylitis. Skin and kidney biopsies of selected patients were stained to detect deposited C3b as a
marker of local complement activation.
Results: Biomarkers of activation of all complement pathways were increased in SSc compared with healthy controls
and were similar to those in other rheumatic diseases. When patients with SSc were divided into subgroups, a distinct
pattern of complement markers was observed in individuals with scleroderma renal crisis (SRC). By functional assay,
we confirmed a significant decrease in complement haemolytic activity in SRC vs. non-SRC patients, indicating
complement consumption. Further, we detected glomerular deposits of C3b in some patients with SRC.
Conclusions: The data indicate that complement activation is an important feature of SRC.
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Background
Scleroderma, also termed systemic sclerosis (SSc), is an
autoimmune disease of connective tissue. Its pathology
involves excessive collagen production, resulting in fibro-
sis of skin and internal organs [1, 2]. This condition is
accompanied by microangiopathy of varying severity and
locations, most obviously seen as Raynaud’s phenomenon.
The most widely accepted classification distinguishes two
main subtypes: limited cutaneous SSc (lcSSc) and diffuse
cutaneous SSc (dcSSc) [3]. In the latter case, internal
organs, most typically the kidneys, gastrointestinal tract,
heart and lungs, are more severely affected. There is an
ongoing discussion about the primary cause of SSc be-
cause many molecular patterns and various pathways have
been found to be involved in the pathogenesis. Import-
antly, 90% of patients with SSc present with autoanti-
bodies to intracellular components such as topoisomerase,
centromeres, histones, RNA polymerases or ribonucleases,
and these patients also show an increase in surface density
of CD19 on their B cells [2]. It has been shown that the
presence of these autoantibodies represents specific
phenotypes of the disease, but less is known about their
pathogenic role.
Data from in vivo models show that low expression of
CD19 affects B-cell proliferation, whereas overexpression
potentiates antibody production and increases the degree
of autoantibodies [4]. Indeed, whole-genome microarray
analysis has demonstrated that gene expression patterns
characteristic of plasma cells decreases more than 90%
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upon anti-CD19 treatment and correlates with inhibition
of collagen expression [5]. Apart from intracellular com-
ponents, protein complexes present on the surface of
fibroblasts, lymphocytes and endothelial cells are also
targets of autoantibodies in SSc [6]. These autoantibodies
may activate fibroblasts to produce collagen, either
directly or indirectly, by fuelling local inflammation and
release of pro-inflammatory cytokines. However, it is un-
clear to what extent the complement system, for which
antibodies are a main trigger, contributes to SSc pathogen-
esis. CD21 (CR2), a receptor on the surface of B cells,
binds activation products of the main complement factor
C3b. Following complement activation, C3b covalently
binds target surfaces and forms transient enzymatic com-
plexes: complement convertases such as C3bBbP, which
fuel downstream events of the cascade such as release of
the potent pro-inflammatory anaphylatoxin C5a, and for-
mation of terminal complement complexes (TCCs), which
can cause cell lysis. CD21 and CD19 associate and form a
signal transduction complex capable of enhancing B-cell
responses to antigen once CD21 binds complement
degradation fragments [7].
In fact, over the last 30 years, researchers have tried to
correlate the levels of complement proteins, markers of
complement activation and circulating immune com-
plexes in patients’ bloodstream with severity of SSc and
different subtypes of the disease. Elevated immune com-
plexes were found only in some patients and were not
associated with clinical or serological features [8, 9]. In
another study, low-molecular-weight markers of comple-
ment activation—Ba, C3d and C4d—were measured by
nephelometry in plasma of patients with SSc [10]. The
results showed that C3d, C4d and Ba fragments, as well as
C3d:C3 and C4d:C4 ratios, were clearly higher in patients
with SSc than in healthy control subjects, indicating in-
creased complement activation. Also, patients with dcSSc
showed significantly higher values than those with lcSSc
[10]. On the basis of observations of higher C4d values in
patients with SSc and subendothelial deposition of im-
mune complexes [11], the classical complement pathway
may indeed play a role in the pathogenesis of SSc. How-
ever, this should be confirmed in a larger number of
patients and with validated methods capable of specifically
measuring products of complement activation.
We recently established a novel enzyme-linked im-
munosorbent assay (ELISA) that can reliably detect
soluble C4d in plasma [12]. In the present study, we re-
examined the usefulness of C4d as biomarker in a cohort
of 122 patients with SSc. Also, we measured a soluble
marker of alternative pathway activation, C3bBbP, and
soluble TCC (sTCC), a marker of the final step of com-
plement activation via any pathway in the same cohort.
In order to compare the results obtained for patients
with SSc with those for patients with other autoimmune
diseases in whom activation of the complement system
was previously reported, we performed the same ana-
lyses in patients with rheumatoid arthritis (RA) [13],
psoriatic arthritis (PsoA) [14] and ankylosing spondylitis
(AS) [15], as well as in healthy control subjects.
Methods
Patients
Plasma samples were collected from 122 patients who
fulfilled the American College of Rheumatology (ACR)
criteria for SSc [16]. The disease was classified as dcSSc
(n = 41) or lcSSc (n = 81), based on the extent of skin
involvement [3]. Samples were collected within a mean
(±SD) of 7.5 (8.5) years of disease onset, which was de-
fined as the first non-Raynaud’s manifestation. A sum-
mary of baseline characteristics of patients with SSc is
presented in Table 1. Healthy control plasma samples
were collected from 47 age-matched (mean 52.3 ±
8.7 years) and sex-matched (14 males, 33 females) healthy
volunteers with no history of rheumatologic disease. All
plasma samples were retrieved in a standardised fashion
(non-fasting) and were stored at −80 °C after centrifuga-
tion until the experiments. Additionally, we included
plasma samples from age- and sex-matched patients with
RA (n = 81), PsoA (n = 22) and AS (n = 20). All patients
with RA fulfilled the 1987 ACR criteria [17]. Diagnoses of
PsoA and AS were based on clinical judgment by the
treating physician and included radiographic examinations
when applicable. All patients with AS had axial involve-
ment but no clinical signs of peripheral arthritis, whereas
the patients with PsoA had peripheral arthritis but no
clinical signs of axial involvement.
Clinical data
Anti-nuclear antibodies (ANA) and anti-centromeric
antibodies (ACA) were analysed by an indirect immuno-
fluorescence technique using the human Hep-2 cell line
as a substrate; anti-topoisomerase I antibodies (ATA)
Table 1 Clinical features at the time of blood sampling of 122
patients with systemic sclerosis
Feature Data
Age, years 56.4 (14.8)
Disease duration, years 7.5 (8.5)
mRSS, points 11.1 (11.0)
Sex, male/female, n (%) 22 (18)/100 (82)
Subset, lcSSc/dcSSc, n (%) 81 (66)/41 (34)
Ab, ACA/ATA/ARA/ANA+/ANA−, n (%) 34 (28)/22 (18)/17
(14)/40 (33)/9 (7)
Abbreviations: Ab Autoantibodies, mRSS Modified Rodnan skin score, lcSSc
Limited cutaneous systemic sclerosis, dcSSc Diffuse cutaneous systemic sclerosis,
Ab Autoantibodies, ACA Anti-centromere, ATA Anti-topoisomerase I, ARA Anti-RNA
polymerase III, ANA+ Anti-nuclear but not anti-centromere, anti-topoisomerase I
or anti-RNA polymerase III autoantibodies, ANA− No anti-nuclear autoantibodies
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were analysed by ELISA; and anti-RNA polymerase III
antibodies (ARA) were analysed by immunoprecipita-
tion. Serum cartilage oligomeric matrix protein (COMP)
was measured with a commercial sandwich ELISA using
two monoclonal antibodies directed against separate
antigenic determinants (AnaMar, Lund, Sweden) [18].
Subjects were classified as having dcSSc or lcSSc accord-
ing to LeRoy et al.’s criteria [3]. The severity of skin in-
volvement was determined by the modified Rodnan skin
score (mRSS) [19]. Disease duration was determined as
the time from the first non-Raynaud’s manifestation.
Measurement of complement activation markers
Plasma concentrations of C4d [12], C3bBbP [20] and
sTCC [20] were measured by specific sandwich ELISAs in
plasma ethylenediaminetetraacetic acid (EDTA) samples
as described previously. Readout of each of these assays
was given in complement activation units (CAU), a de-
fined arbitrary unit set for the International Complement
Standard #2 (ICS#2) sample, which is serum-pooled from
about 1000 healthy individuals and incubated with activa-
tors of all three complement pathways [20].
Haemolytic assays
Plasma EDTA samples collected from patients with SSc
were tested for activity of classical or alternative comple-
ment pathways by haemolytic assays performed as
described elsewhere [21], with small modifications.
Briefly, the classical complement pathway was activated
on antibody-sensitised sheep erythrocytes. To overcome
the inhibitory effect of EDTA, plasma samples were
diluted 1:100 in DGVB2+ buffer (2.5 mM veronal buffer,
pH 7.35, 72 mM NaCl, 140 mM glucose, 0.1% gelatin,
1 mM MgCl2 and 0.15 mM CaCl2). For the alterna-
tive pathway, plasma samples were diluted 1:20 in
Mg-ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tet-
raacetic acid (Mg-EGTA) buffer (2.5 mM veronal buffer,
pH 7.3, 70 mM NaCl, 140 mM glucose, 0.1% gelatin,
7 mM MgCl2 and 10 mM EGTA) and added directly to
rabbit erythrocytes.
Immunohistochemical staining of C3
Kidney and skin biopsies collected from patients with
SSc were fixed in formalin and embedded in paraffin.
Sections of 4-μm thickness were cut and automatically
pre-treated using the PT Link system (Dako/Agilent
Technologies, Santa Clara, CA, USA) and then stained
in an Autostainer Plus (Dako) with rabbit anti-human
C3c polyclonal antibody (P0062; Dako) at a final dilution
of 1:5000 for 30 minutes. Subsequently, the EnVision
Flex HRP kit (Dako) was applied to the sections for
20 minutes to detect primary antibodies, followed by
3,3′-diaminobenzidine (DAB) reagent for visualisation.
Statistical analysis
Obtained data on the appearance of complement activa-
tion markers and haemolytic activity were not distributed
normally; in each complement measurement there were
outliers, and some patient subgroups were rather small.
Therefore, we used non-parametric statistical methods
throughout the whole analysis. The Kruskal-Wallis and
Mann-Whitney U tests were used to compare multiple
groups or two groups, respectively. Spearman’s correlation
was used to analyse relationships. p values <0.05 were
considered significant. Calculations were performed with
Prism 5.0 (GraphPad Software, La Jolla, CA, USA) and
IBM SPSS Statistics version 20 (IBM, Armonk, NY, USA)
software.
Results
The complement system is activated in patients with
autoimmune diseases
We tested three different complement activation markers:
(1) C4d, corresponding to activation of the classical
pathway; (2) the fluid-phase alternative C3 convertase
(C3bBbP), reflecting activation of the alternative pathway
as well as the amplification loop enhancing the cascade at
the level of convertases; and (3) sTCC, which evaluates
the lytic (terminal) pathway (Fig. 1). All autoimmune pa-
tients, regardless of diagnosis, had 5- to 15-fold increased
levels of all three markers, thus confirming ongoing com-
plement activation. Regarding SSc, C4d was increased to a
similar degree as for AS and PsoA, but to a lesser extent
than in RA (p = 0.05 by Kruskal-Wallis test). Interestingly,
the alternative pathway was activated significantly more
strongly in patients with SSc than in patients with RA
(p < 0.001). All groups of patients showed similar levels
of sTCC. As expected, healthy control subjects showed
low levels of all three markers.
Correlations of complement activation markers in
patients with autoimmune diseases
Because sTCC is a marker of the terminal complement
pathway, which is fuelled by all complement pathways, we
analysed which of the early complement markers correlate
to appearance of sTCC in patients with SSc and other
autoimmune diseases. Only C3bBbP, and not C4d, was
significantly correlated to sTCC in all groups of patients.
However, in patients with RA, C4d was significantly corre-
lated to C3bBbP, which may indicate the role of the ampli-
fication of the classical pathway via alternative convertases
in overall complement activation in this patient group.
Correlation coefficients and p values are given in Table 2.
Correlations of complement activation markers to mRSS
and COMP
To find out whether complement activation correlates to
the severity of fibrosis expressed by mRSS, we performed
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Spearman’s correlation analysis and found weak, bor-
derline significant correlation between mRSS and C4d
(Table 3). Furthermore, COMP, which is expressed by
fibroblasts in SSc, is associated with mRSS [22] (in the
present cohort, Spearman’s r = 0.47, p = 0.0005) and is
known to activate the alternative pathway [23]. How-
ever, we did not observe a statistically significant correl-
ation between complement activation markers and
COMP levels in plasma, implying that it is likely not a
major complement trigger in these patients, at least not
when released into blood.
Analyses of complement activation markers in the
subgroups of patients with SSc
We classified the patients into subgroups depending on
the form of disease (lcSSc vs. dcSSc); typical complica-
tions, such as pulmonary arterial hypertension (PAH),
scleroderma renal crisis (SRC), pitting scars, ulcers, telan-
giectasias; or the presence of certain types of anti-nuclear
autoantibodies, including ACA, ATA, ARA, ANA without
ACA, ATA or ARA, and finally ANA-negative. We did
not observe significant differences in C4d, C3bBbP and
sTCC levels between men and women or between patients
with lcSSc and those with dcSSc (Table 4). Also, concentra-
tions of these markers were equally distributed within
patients with and without PAH, pitting scars, ulcers, and
telangiectasias. Importantly, a different distribution of
complement activation markers was detected in pa-
tients with SRC, who had significantly higher amounts
of C4d (p = 0.036) and significantly lower levels of
C3bBbP (p < 0.001) and sTCC (p = 0.003) than patients
without kidney involvement. When overall distribution
of autoantibodies was analysed by the Kruskal-Wallis test,
we found a significant difference for sTCC (p = 0.016)
and a difference on the border of significance for
C3bBbP (p = 0.055). Although not statistically signifi-
cant (p = 0.095), there was a trend for C4d, according
to which patients without any antinuclear autoantibodies
presented with low levels of this marker. Furthermore, pa-
tients with ARA positivity showed a pattern of complement
activation markers similar to that of the patients with SRC
(high C4d, low C3bBbP and TCC). Additional Kruskal-
Wallis analysis performed for a single type of autoanti-
body revealed that the ARA-positive group differed
Table 2 Correlations between complement biomarkers C4d, C3bBbP and terminal complement complex in plasma samples from
patients with autoimmune diseases
Disease C4d-TCC correlation C3bBbP-TCC correlation C4d-C3bBbP correlation
Spearman’s r p value Spearman’s r p value Spearman’s r p value
SSc (n = 122) −0.06 0.47 0.47 <0.0001a 0.099 0.27
RA (n = 81) 0.12 0.29 0.41 0.0001a 0.26 0.018b
PsoA (n = 22) 0.035 0.88 0.52 0.013b 0.086 0.70
AS (n = 20) −0.33 0.15 0.52 0.019b −0.20 0.40
Abbreviations: AS Ankylosing spondylitis, PsoA Psoriatic arthritis, RA Rheumatoid arthritis, SSc Systemic sclerosis, TCC Terminal complement complex
ap <0.001
bp < 0.05
Fig. 1 Complement activation markers in systemic sclerosis and other autoimmune diseases. Graphs show mean and standard deviation of C4d
(left panel), C3bBbP (middle panel) and soluble terminal complement complex (TCC) (right panel) concentrations. Value obtained for each patient
(depicted with single points) is an average of two independent experiments. Statistical analysis was performed by Kruskal-Wallis test with Dunn’s
multiple comparisons post-test, and statistical significance was set at *p < 0.05 and ***p < 0.001.Abbreviation: CAU Complement activation units
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significantly from patients without any antinuclear anti-
bodies (ANA-negative) at a p level <0.05 for all comple-
ment markers. Also, the ARA-positive group had
significantly lower amounts of C3bBbP and TCC than
ARA-negative patients (p < 0.01). Interestingly, 8 (47%) of
17 patients with ARA presented also with SRC, a group
that accounted only for 15% of all patients with SSc (18
of 122). Taken together, patients with ARA were, as ex-
pected, overrepresented among those with SRC and,
importantly, manifested the same pattern of comple-
ment activation markers.
Haemolytic activity of plasma samples collected from
patients with SSc
The levels of C3bBbP and sTCC in the SRC group
(means 656 CAU and 4.22 CAU, respectively) were
lower than in other patients with SSc; however, these
levels were still considerably higher than analogous
means for healthy control subjects (79.7 CAU and 1.64
CAU, respectively), indicating that complement activa-
tion takes place during the renal crisis. At the same time,
C4d, which is a marker of classical pathway activation
Table 3 Correlations of complement activation markers with age,
modified Rodnan skin score and cartilage oligomeric matrix protein
n C4d p value C3bBbP p value TCC p value
Age 122 −0.14 0.13 −0.083 0.36 0.017 0.86
mRSS 118 0.17 0.06 −0.16 0.087 −0.082 0.38
COMP 53 0.16 0.26 −0.052 0.71 0.092 0.51
Abbreviations: COMP Cartilage oligomeric matrix protein, mRSS Modified
Rodnan skin score, TCC Terminal complement complex
Table 4 Analyses of complement activation markers in the subgroups of patients with systemic sclerosis
n C4d, mean (SD) p value C3bBbP, mean (SD) p value TCC, mean (SD) p value
Sex 0.96 0.20 0.87
Male 22 35.6 (40.3) 913 (574) 5.80 (3.69)
Female 100 29.2 (18.3) 1119 (661) 8.39 (15.8)
Subset 0.88 0.11 0.36
lcSSc 81 30.1 (25.2) 1143 (655) 8.56 (16.4)
dcSSc 41 30.8 (20.7) 962 (629) 6.66 (9.34)
PAH 0.19 0.75 0.76
No 96 31.8 (25.3) 1069 (645) 7.50 (12.4)
Yes 26 25.0 (16.0) 1131 (676) 9.49 (20.5)
SRC 0.036 <0.001 0.003
No 104 28.9 (23.7) 1156 (655) 8.57 (15.4)
Yes 18 38.6 (22.9) 656 (423) 4.22 (5.54)
Ab 0.095 0.055 0.016
ACA 34 30.7 (16.9) 1029 (594) 5.83 (5.70)
ATA 22 32.7 (18.8) 1140 (744) 10.8 (22.0)
ARA 17 35.0 (22.5) 761 (560) 3.19 (2.59)
ANA+ 40 29.5 (32.2) 1195 (642) 10.6 (18.0)
ANA− 9 18.1 (10.0) 1244 (705) 5.62 (3.36)
Pitting scar 0.50 0.35 0.76
No 68 31.0 (26.1) 1071 (658) 9.30 (18.6)
Yes 50 28.6 (19.0) 1155 (633) 6.53 (5.62)
Ulcer 0.35 0.36 0.54
No 105 30.5 (23.9) 1090 (656) 8.31 (15.3)
Yes 14 25.5 (17.8) 1183 (574) 6.19 (6.53)
Telangiectasias 0.83 0.19 0.39
No 56 28.5 (17.8) 1003 (586) 6.07 (3.80)
Yes 63 31.2 (27.2) 1189 (687) 9.84 (19.6)
Abbreviations: PAH Pulmonary arterial hypertension, SRC Scleroderma renal crisis, Ab Autoantibodies, ACA Anti-centromere, ATA Anti-topoisomerase I, ARA Anti-RNA
polymerase III, ANA+ Anti-nuclear but not anti-centromere, anti-topoisomerase I or anti-RNA polymerase III, ANA− No anti-nuclear autoantibodies, dcSSc Diffuse cutaneous
systemic sclerosis, lcSSc Limited cutaneous systemic sclerosis, TCC Terminal complement complex
Autoantibody analyses were by Kruskal-Wallis test; all others were by Mann-Whitney U test
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and the end-degradation product of C4b component, in-
creased to significantly higher levels than in the non-
SRC group. One possible explanation for these observa-
tions is that during SRC the classical pathway is strongly
initiated by autoantibodies, and then an amplification
loop driven by the alternative pathway takes over the
cascade, leading to systemic depletion of its components,
including C3 and factor B proteins. Such depletion is
also reflected in a reduction of soluble sTCC compared
with patients with no SRC episodes. To confirm the sce-
nario of ongoing complement consumption in SRC, we
analysed haemolytic activity of plasma samples from pa-
tients with SSc. Residual complement activity was exam-
ined in assays testing the classical and alternative
pathways (Fig. 2). Of all classifications made for the whole
SSc cohort, only the SRC-positive group showed signifi-
cantly lower haemolytic activity in the alternative pathway
(p = 0.0107) and a borderline significant drop of haemo-
lytic activity in the classical pathway (p = 0.063), which
confirmed systemic complement depletion, most probably
at the level of alternative convertases.
C3 staining in kidney biopsies from patients with SRC
Because the SRC subgroup showed a distinct pattern of
complement activation markers, we searched for the pri-
mary source of a putative strong complement activation
deduced from lower levels of C3bBbP and lower haemo-
lytic activity of plasma samples. Kidney biopsies from 5 of
18 patients with SRC included in the study were available,
and we examined these for C3b deposition by immunohis-
tochemistry. C3b deposits were detected in glomeruli of
two patients and in tubules of one more patient (Fig. 3),
whereas C3b staining was negative for kidneys of two
remaining patients. These findings indicate that ongoing
complement activation in kidneys may be one of the hall-
marks of SRC. However, it does not explain all cases, and
other sources of activation are also plausible.
C3b staining in skin biopsies from ARA+, ARA− and
ARA−/ACA+ patients
Searching for further explanations for complement acti-
vation in patients with SRC, we followed the overrepre-
sentation of ARA-positive patients in the SRC group
Fig. 2 Haemolytic activity of plasma samples collected from patients with systemic sclerosis. Left column shows classical pathway haemolytic
activity of 1% plasma, and right column shows alternative pathway activity of 5% plasma. Value of 1 on y-axis corresponds to the readout of
normal human plasma (NHP). Results are means ± standard deviation derived from two independent experiments, and statistical significance is
set at *p < 0.05 according to Mann-Whitney U test.Abbreviations: SRC Scleroderma renal crisis, PAH Pulmonary arterial hypertension, lcSSc Limited
cutaneous systemic sclerosis, dcSSc Diffuse cutaneous systemic sclerosis. Graphs comparing the patients with vs. without ulcers, pitting scars and
telangiectasias are not shown, because the differences between groups did not reach statistical significance
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and analysed C3b deposition in skin biopsies obtained
from ARA+, ARA− and ARA−/ACA+ patients. Material
from four patients in each group was available. We
observed C3b deposition in skin tissue from all ARA+
patients, but other groups also had at least two of four
slides that were positive (Fig. 4), so there was no dra-
matic difference between the groups. The staining was
localised to the dermal layer and most prominent in the
endothelium of small dermal arteries. Less staining was
associated with the collagenous fibres of the dermis. In
the basal layer of the epidermis, cells were discovered
containing what seemed to be stain. However, these
cells were melanocytes, and the pigment was melanin,
not DAB chromogen (Fig. 4).
Discussion
Reliable measurement of complement activation is not a
trivial task. Of two possible strategies, measurement of na-
tive complement protein consumption and measurement
of markers appearing only after complement activation,
the latter seems to be more reliable. This is due partly to
large interpersonal differences in some complement pro-
teins, such as that normal concentration of the main com-
plement protein C3 ranges from 0.8 to 1.8 mg/ml. On one
hand, these levels are affected by both consumption
and a changing rate of synthesis because many comple-
ment factors are acute-phase response proteins. On the
other hand, challenges in the strategy of measuring
products of activation relate to the specificity of
Fig. 3 C3b deposition in kidney biopsies from patients with scleroderma renal crisis (SRC). Shown are representative micrographs of kidney
biopsy cores immunostained for C3b. a An example of a biopsy obtained from a patient with SRC, which was negative for C3b. b Example of a
biopsy positive for C3b in glomeruli. c Example of a biopsy positive for C3b in tubules. d Positive control biopsy from patient diagnosed for
immunoglobulin A nephropathy with distinct glomerular C3 positivity
Fig. 4 C3b staining of skin biopsied from anti-RNA polymerase III (ARA+), ARA− and anti-centromere-positive (ACA+)/ARA− patients. Shown are
representative micrographs of skin biopsies immunostained for C3b. Four patients per group (rows) were available for the study. In most images,
the endothelium of the dermal arterioles is distinctly positive. There is also a fainter staining associated with the dermal collagen strands. In the
basal layer of the epidermis, melanocytes are seen, filled with melanin pigment but negative for C3b
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antibodies, which must target only neoepitopes local-
ised on processed complement proteins and not epi-
topes on ubiquitous, native molecules. Previous studies
performed with 34 patients with SSc revealed higher
levels of C4d in blood of patients with dcSSc than in
patients with lcSSc, suggesting that C4d content may
be associated with clinical severity of SSc [10]. How-
ever, the authors of that study did not use specific anti-
C4d antibodies; instead, they performed precipitation of
high-molecular-weight plasma proteins and detected
C4d in supernatant with whole antiserum by nephelom-
etry. We re-examined this hypothesis using plasma
samples of 122 patients with our recently designed C4d
ELISA. The advantage of this method over nephelome-
try and other, previously used C4d immunoassays is
that it uses a novel antibody specific to a 5-aa linear
cleavage site neoepitope. Previously, we showed that
the readout of this assay is unaffected by repeated
freezing-thawing or heating of samples, which is not
the case for some other techniques based on conform-
ational neoepitopes [12]. We noticed a clear increase of
C4d as well as the complement activation markers
C3bBbP and sTCC in patients with SSc as well as in
patients with other rheumatic diseases compared with
healthy control subjects (Fig. 1). However, we could
confirm neither a link between clinical severity of SSc
and C4d content nor associations of complement acti-
vation markers with particular syndromes characteristic
for SSc, except for SRC.
Renal crisis is reported typically in 5–10% patents with
SSc [24, 25]. Historically, this group of patients had a
high risk of death (up to 85% mortality after 1 year [26]),
and even after introducing treatment with angiotensin-
converting enzyme inhibitors, mortality remains rela-
tively high at 18% after the first year and 41–58% after
5 years [27, 28]. To prevent loss of kidney function and
other associated complications, such as systemic hyper-
tension, retinopathy or pulmonary oedema, patients re-
quire early identification and aggressive treatment [25].
Therefore, increasing knowledge about underlying
pathomechanisms of SRC is necessary. Our data sug-
gest that activation of complement, which is a feature
common to rheumatic and/or autoimmune diseases
[13, 29], presents differently in patients with SSc with
SRC. Another important observation was that the same
pattern of complement activation markers seen in SRC was
observed in the group of ARA-positive patients, which
accounted for 44% of patients with SRC in our study and
33% [30] to 59% [27] in other studies. Trends and a signifi-
cant increase of C4d marker in these two groups of patients
linked to each other speak for enhanced activation of the
classical pathway. C3bBbP is a marker that may indicate ac-
tivation of the alternative pathway alone or as an amplifica-
tion loop of the classical or lectin pathway. At first glance,
elevated C4d and decreased C3bBbP levels in the same pa-
tients may appear contradictory, but the nature of these
markers may provide a logical explanation. Whereas C4d is
the end degradation product of an early component of the
classical pathway C4b and may accumulate over time,
C3bBbP is a fluid-phase convertase, an enzymatic complex
that converts available C3 into C3b. Activation of the alter-
native pathway leads to depletion of C3 and factor B and,
by doing so, limits de novo formation of C3bBbP. However,
C3bBbP decays both spontaneously and with the aid of sev-
eral complement inhibitors [20]. As a result of limited
replacement of alternative pathway components and
pathway exhaustion, patients with acute episodes of
complement activation may present with lower C3bBbP
content than those with chronic disease. The same is true
for sTCC.
On the basis of our results, we hypothesised that acute
complement activation takes place during the onset of
SRC and that depletion of available complement is an-
other consequence of such scenario. Our hypothesis was
confirmed by haemolytic assays in which residual com-
plement activity of plasma from patients with SRC was
significantly lower than that in non-SRC subjects. In
conjunction with a previous report showing increased
C4d deposition in peritubular capillaries of patients with
SSc with SRC compared with normotensive controls and
hypertensive non-SRC control subjects [24], we should
consider local complement activation as an important
element of the SRC pathomechanism. This hypothesis is
strengthened by presence of C3b deposits, which reflect
complement activation via all pathways, in three of five
analysed kidney biopsies from patients with SRC. We
also tested whether ARA-positive patients overrepre-
sented in the SRC group had increased C3b deposits in
skin. Although all ARA-positive individuals showed C3b
staining in skin biopsies, we also found it in some ARA-
negative patients. Therefore, we hypothesise that local
complement activation in kidneys and skin takes place
during SRC, but that this phenomenon is probably not
limited only to this subgroup and that other, distinct
features may be characteristic for renal involvement.
Nonetheless, complement activation may be a strongly
contributing factor in some patients with SRC, and these
patients could be considered for treatment with emer-
ging complement inhibitors such as eculizumab, which
is now used in therapy for another kidney disease with
complement involvement: haemolytic uremic syndrome.
Conclusions
The present study shows that biomarkers of activation
of all complement pathways measured with improved
assays were increased in patients with SSc compared
with healthy control subjects. Patients with SSc with
SRC showed a distinct pattern of complement markers
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indicating ongoing complement consumption. This,
finding, together with glomerular deposits of C3b found
in some of these patients, indicates that complement
activation is an important feature of SRC.
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